EP
LRMR icon

Essential Partners’s Larimar Therapeutics LRMR Stock Holding History

Essential Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.55K Sell
2,050
-904
-31% -$3.5K ﹤0.01% 1385
2026
Q2 		$9.01K Sell
2,954
-2,276
-44% -$9.04K ﹤0.01% 1261
2026
Q1 		$23.5K Buy
5,230
+3,719
+246% +$14.9K 0.01% 866
2025
Q4 		$5.76K Sell
1,511
-12
-0.8% -$47 ﹤0.01% 1373
2025
Q3 		$4.92K Buy
1,523
+43
+3% +$161 ﹤0.01% 1433
2025
Q2 		$4.28K Buy
+1,480
New +$3.43K ﹤0.01% 1097

Other funds holding LRMR

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Essential Partners's LRMR Position: Q3 2026 in Review

Essential Partners reduced its Larimar Therapeutics (LRMR) stake by 31% in Q3 2026, selling an estimated $3.5K and leaving 2,050 shares worth $6.55K. The position accounts for ﹤0.01% of the portfolio, ranked #1385.

Essential Partners first reported a position in LRMR in Q2 2025 and has held it in 6 quarters since. The position peaked at $23.5K in Q1 2026. 7 funds tracked by Wall St. Rank hold LRMR as of Q3 2026.

  • Essential Partners held 2,050 shares of Larimar Therapeutics worth $6.55K as of Q3 2026.
  • Essential Partners sold 904 Larimar Therapeutics shares in Q3 2026, an estimated $3.5K.
  • Larimar Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1385 holding.
  • Essential Partners first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Larimar Therapeutics position peaked at $23.5K in Q1 2026.
  • 7 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.